Finally, the lower concentration of each drug administered in the combination as compared to single agent might translate in a favorable tolerability of this combination that will be explored in future clinical trials.
Translation Relevance
Potential synergistic effects between two important epigenetic regulators are under investigation in phase I/II clinical trails in refractory hematologic malignancies as well as solid tumors. Nevertheless, studies exploring the potential synergistic interactions and insight to the molecular mechanism of such combination therapy is lacking in CTCL. In addition, there has been no common functional mutation or genetic aberration identified to be responsible for malignant transformation of T cells in CTCL. In this study, we describe, the synergistic effect of romidepsin and azacitidine in CTCL cell lines and tumor cells derived from SS patients as well as demonstrate the potential underlying mechanisms and global methylation profile alterations effecting gene expression with potential predictive value in CTCL.
Finally, the lower concentration of each drug administered in the combination as compared to single agent might translate in a favorable tolerability of this combination that will be explored in future clinical trials.
Introduction
CTCL comprise a heterogeneous group of malignancies derived from skin-homing T cells. The more common subtypes are mycosis fungoides (MF), and Sézary syndrome (SS), an aggressive leukemic variant of CTCL (1) . These two subtypes account for approximately 70-75% of all cases (2) . Therapeutic options include skin directed therapy and/or systemic therapy (3) . The success rate of most available therapy regimens ranges from 30 to 50%, but relapse is common and difficult to treat, and curative therapy remains elusive. Therefore, there is an indisputable need for more successful treatment approaches for advanced CTCL.
Romidepsin (F228 or desipeptide) is a potent bicyclic histone deacetylase (HDAC)
inhibitor approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed/refractory CTCL patients on the basis of two phase II clinical trials showing an overall response rate of 34-35% (4).
Azacitidine (5-azacytidine or Vidaza®) is a cytotoxic cytidine analog and DNA methyltransferase inhibitor with anti-neoplastic activity (5) . At lower concentrations, it is known to relieve the transcriptional repression of various tumor suppressor genes that were silenced via hypermethylation of their promoter region (6) . It was approved by the FDA for treatment of refractory myelodysplastic syndromes (MDS) (7) .
In cancer, tumor suppressors are often down-regulated by aberrant histone deacetylation and/or DNA methylation (8) . HDAC inhibitors can synergize with Author Manuscript Published OnlineFirst on December 9, 2015; DOI: 10.1158/1078-0432.CCR- demethylating agents to relieve this transcriptional repression (9) . Moreover, combined epigenetic therapies have been shown to be effective in hematological malignancies (10) (11) (12) (13) .
Here, we demonstrate that the combination of romidepsin and azacitidine exerts synergistic anti-proliferative effects by inducing apoptosis in CTCL cell lines as well as CD4+ T cells derived from SS patients with high tumor burden. We show the tumor suppressor gene RhoB as a potential regulator of the synergism, whose anti-neoplastic relevance has been described in other malignancies (14) (15) (16) . Furthermore, our data suggest that the combination treatment results in a unique global methylation pattern in CTCL, which may contribute to increased efficacy of the anti-proliferative effects of the combination treatment in CTCL.
Research. 
Material and Methods

Cell lines
MyLa, SeAx and Hut78, well established CTCL cell lines (17, 18) , were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), glutamine (2 mM) and streptomycin (100 μg/ml) at 37°C, 5% CO2 and 95% humidity.
Cell viability assay
The MTT (Sigma-Aldrich, St Louis, MO, USA) assay measures the activity of cellular enzymes that reduce the tetrazolium dye, to its insoluble form, formazan, which under defined conditions can reflect the number of viable cells. This assay was utilized to measure cell proliferation in untreated and treated CTCL cell lines, SS patients and healthy donors PBL samples. The absorbance was measured by spectrophotometery, using a 550 nm wavelength ELISA reader. Author Manuscript Published OnlineFirst on December 9, 2015; DOI: 10.1158/1078-0432.CCR- necrotic, apoptotic and normal cells in the above described populations. The proportion of cells that exhibited sub-G1 phase of the cell cycle, indicate DNA degradation and apoptotic cell death. After the designated treatment time cells were harvested in 0.3 mL of cold PBS and then fixed with cold 70% ethanol, left incubating on ice for 1 hour, and washed twice with cold PBS. RNase A (10 mg/mL) was added to each sample and incubated at 37°C for 1 hour. Cells were acquired using a BD FACS Canto flow cytometry using the FL2-A channel and analyzed with the FlowJo software 8.5.2.
Western blot analysis
Cells were washed twice with cold phosphate-buffered saline and lysed at 4°C in RIPA protein lysis buffer. The protein concentration of each sample was determined by 
Immunohistochemistry
After incubation of CTCL cell lines with romidepsin and azacytidine simultaneously for 48 hours, the samples were placed on the slides using the cytospin procedure, as previously published (19) . After fixation in 10% acetone the slides were incubated with the RhoB primary antibody (C-5, mouse monoclonal, Santa Cruz Biotechnology, Dallas, TX, USA), and then secondary antibody as suggested by manufactures' protocol.
Primary Sézary cells and healthy donors CD4+ T-cells
Sample collection and laboratory studies were in compliance with institutional review 
Compounds and Reagents
Romidepsin and azacitidine were provided by Celgene (Summit, NJ, USA).
Statistical analysis
The median dose effect (21) (or half the maximal inhibitory concentration [IC 50 ]) values for each cell line at different time points were determined using CompuSyn software (22) based on the quantitative analysis of dose-effect relationships multiple drugs or enzyme
antiproliferative effects were reached with azacitidine 2.5uM for 4 days and romidepsin 2.5nM was added for the last 24 hours. This combination was used in the patient derived samples for further experiments.
A significant synergistic effect on cell viability and induction of apoptosis was evident, measured by the MTT assay (Figure 3a) and by flow cytometry after Annexin V/PI staining (Figure 3b-c 
Discussion
In many other malignancies, characteristic chromosomal abnormalities have been identified as therapeutic targets, such as bcr-abl fusion gene in chronic myelocytic leukemia (CML) and BRAF status in melanoma. In CTCL, various cytogenetic studies found multiple genetic alterations that recur in a subset of MF and/ or SS patients (36) (37) (38) . But few common genetic variants including targetable mutations have been identified (39) .
Hence, over the past decade there has been an emergence of studies exploring the involvement of epigenetic mechanisms that contribute to the pathogenesis of CTCL (40) (41) (42) . These data are limited to only molecular assessments or identification of epigenetic changes as prognostic markers. 
administered in the combination was almost fifty percent less than the IC50 of each agent. This might translate in a favorable tolerability of this combination that will be explored in future clinical trials.
Intriguingly, the combination induced the re-expression of the tumor suppressor gene, RhoB, as early as 6 hours post-treatment. This could be explained by the rapid induction of RhoB in response to early stress to trigger pathways involved in DNA damage response and cell death. RhoB is believed to be a central factor in growth inhibition of transformed cells (15, 29, 44) . Investigations in multiple cancers have found that RhoB is rarely mutated in cancer genomes (45) . Additionally, there is no known aberrant methylation at its promoter region that could be responsible for the loss of RhoB expression, as others (32) and we have shown. Therefore, histone modifications or other transcriptional regulatory mechanism may be responsible for the loss of RhoB expression. Pre-clinical data suggests increased histone acetylation at the RhoB promoter region results in its re-expression in lung carcinoma and anaplastic thyroid cancer (30, 34) . In our study, the combination treatment resulted in significant histone H3 acetylation at the promoter region of RhoB gene compared to romidepsin alone suggesting histone acetylation is responsible for transcriptional activity of RhoB, which is further enhanced by the hypomethylating agent azacitidine. This might be due to the fact that DNA hypomethylation results in a more accessible chromatin for histone acetylation or due to DNA-hypomethylation independent effects of azacitidine that could contribute to the synergistic effects of the combination. It is suggested that RhoB promotes cell cycle arrest by controlling the expression of cell cycle regulators such as p21 (34) . We observed an up-regulation of p21 in cell lines and tumor cells derived from 
